Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) PT at $48.85

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have been given a consensus rating of “Buy” by the fifteen analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, twelve have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $48.85.

Several equities analysts have recently commented on the company. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. BMO Capital Markets began coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price objective on the stock. Royal Bank of Canada restated an “outperform” rating and set a $45.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Chardan Capital restated a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Monday. Finally, Piper Sandler reduced their price objective on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th.

Insider Buying and Selling

In related news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 6,237 shares of company stock valued at $77,760 over the last three months. Company insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors have recently bought and sold shares of the stock. Quantbot Technologies LP acquired a new stake in Dyne Therapeutics during the 3rd quarter worth about $34,000. Point72 DIFC Ltd acquired a new stake in Dyne Therapeutics during the 3rd quarter worth about $36,000. US Bancorp DE boosted its position in Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after acquiring an additional 1,212 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Dyne Therapeutics during the 4th quarter worth about $50,000. Finally, KBC Group NV boosted its position in Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after acquiring an additional 978 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Up 2.2 %

NASDAQ DYN opened at $12.31 on Friday. The stock has a market cap of $1.39 billion, a PE ratio of -3.46 and a beta of 1.11. Dyne Therapeutics has a fifty-two week low of $11.18 and a fifty-two week high of $47.45. The business has a 50 day moving average price of $14.33 and a two-hundred day moving average price of $24.90.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. Sell-side analysts anticipate that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.